Manufacturer profile
Astellas Pharma US, Inc.
Pharmaceutical company4 products tracked
4
products tracked
66,291
total reports
1
recalls on record
77.2%
serious overall
Products
showing 4 of 4
| Product | Approved | Reports ↓ | Top signal | Recalls |
|---|---|---|---|---|
| 2012 | 58,003 | Prostatic specific antigen increased | 1 | |
| 2018 | 3,785 | Differentiation syndrome | 0 | |
| 2015 | 3,425 | Aspergillus infection | 0 | |
| 2024 | 1,078 | Protein-losing gastroenteropathy | 0 |
Recall history · 1 on record
| Date | Class | Reason | Firm |
|---|---|---|---|
| Nov 14, 2014 | II | Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin. | Attix Pharmaceuticals |
Class I = reasonable probability of serious harm · Class II = temporary or reversible · Class III = unlikely to cause harm.
Registration status
Some products from Astellas Pharma US, Inc. are not FDA-registered for human use. For unregistered substances (peptides, SARMs without human registration), no legitimate human-use supplier exists. The absence of a sourcing route is the safety information.